Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Taysha Gene Therapies (TSHA) EPS (Weighted Average and Diluted) (2022 - 2025)

Historic EPS (Weighted Average and Diluted) for Taysha Gene Therapies (TSHA) over the last 4 years, with Q3 2025 value amounting to -$0.09.

  • Taysha Gene Therapies' EPS (Weighted Average and Diluted) rose 1000.0% to -$0.09 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.33, marking a year-over-year decrease of 15238.1%. This contributed to the annual value of -$0.36 for FY2024, which is 6281.25% up from last year.
  • According to the latest figures from Q3 2025, Taysha Gene Therapies' EPS (Weighted Average and Diluted) is -$0.09, which was up 1000.0% from -$0.09 recorded in Q2 2025.
  • Over the past 5 years, Taysha Gene Therapies' EPS (Weighted Average and Diluted) peaked at $0.92 during Q4 2023, and registered a low of -$1.32 during Q1 2022.
  • Its 4-year average for EPS (Weighted Average and Diluted) is -$0.34, with a median of -$0.1 in 2024.
  • Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first soared by 19292.93% in 2023, then tumbled by 10816.3% in 2024.
  • Over the past 4 years, Taysha Gene Therapies' EPS (Weighted Average and Diluted) (Quarter) stood at -$0.99 in 2022, then soared by 192.93% to $0.92 in 2023, then crashed by 108.16% to -$0.08 in 2024, then fell by 19.84% to -$0.09 in 2025.
  • Its EPS (Weighted Average and Diluted) was -$0.09 in Q3 2025, compared to -$0.09 in Q2 2025 and -$0.08 in Q1 2025.